These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7682886)

  • 1. Economic burden of treated benign prostatic hyperplasia in the United Kingdom.
    Drummond MF; McGuire AJ; Black NA; Petticrew M; McPherson CK
    Br J Urol; 1993 Mar; 71(3):290-6. PubMed ID: 7682886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales.
    McGuire A; Irwin DE; Fenn P; Gray A; Anderson P; Lovering A; MacGowan A
    Value Health; 2001; 4(5):370-5. PubMed ID: 11705127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Annual costs of benign prostatic hyperplasia in New Zealand.
    Scott WG; Scott HM
    Pharmacoeconomics; 1993 Dec; 4(6):455-68. PubMed ID: 10151048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK.
    Speakman M; Kirby R; Doyle S; Ioannou C
    BJU Int; 2015 Apr; 115(4):508-19. PubMed ID: 24656222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated total costs of treating benign prostatic hyperplasia in Sweden.
    Ahlstrand C; Carlsson P; Jönsson B
    Scand J Urol Nephrol; 1995 Mar; 29(1):57-63. PubMed ID: 7542399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economics of benign prostatic hyperplasia treatment: a literature review.
    Kortt MA; Bootman JL
    Clin Ther; 1996; 18(6):1227-41. PubMed ID: 9001839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic costs of benign prostatic hyperplasia in the private sector.
    Saigal CS; Joyce G
    J Urol; 2005 Apr; 173(4):1309-13. PubMed ID: 15758787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost of illness of medically treated benign prostatic hyperplasia in Hungary.
    Rencz F; Kovács Á; Brodszky V; Gulácsi L; Németh Z; Nagy GJ; Nagy J; Buzogány I; Böszörményi-Nagy G; Majoros A; Nyirády P
    Int Urol Nephrol; 2015 Aug; 47(8):1241-9. PubMed ID: 26093585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Annual cost of bipolar disorder to UK society.
    Das Gupta R; Guest JF
    Br J Psychiatry; 2002 Mar; 180():227-33. PubMed ID: 11872515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economics of different treatment options of benign prostatic hyperplasia in Turkey.
    Ilker Y; Tarcan T; Akdaş A
    Int Urol Nephrol; 1996; 28(4):525-8. PubMed ID: 9119638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of single-dose tamsulosin and dutasteride combination therapy compared with tamsulosin monotherapy in patients with benign prostatic hyperplasia in the UK.
    Walker A; Doyle S; Posnett J; Hunjan M
    BJU Int; 2013 Sep; 112(5):638-46. PubMed ID: 23356792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Annual cost of erectile dysfunction to UK Society.
    Plumb JM; Guest JF
    Pharmacoeconomics; 1999 Dec; 16(6):699-709. PubMed ID: 10724796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost Comparison of Benign Prostatic Hyperplasia Treatment Options.
    DeWitt-Foy ME; Gill BC; Ulchaker JC
    Curr Urol Rep; 2019 Jun; 20(8):45. PubMed ID: 31218458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia.
    Lowe FC; McDaniel RL; Chmiel JJ; Hillman AL
    Urology; 1995 Oct; 46(4):477-83. PubMed ID: 7571214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia.
    Plosker GL; Goa KL
    Pharmacoeconomics; 1997 Feb; 11(2):184-97. PubMed ID: 10165827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness in the management of benign prostatic hyperplasia: Italian data.
    Di Silverio F; D'Eramo G; Flammia GP; Sciarra A; Buscarini M; Mauro M; Sciarra F
    Minerva Urol Nefrol; 1994 Jun; 46(2):93-9. PubMed ID: 7526475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Economic public health aspects of benign prostatic hyperplasia in Austria].
    Schwarz B; Vutuc C; Kunze M
    Wien Med Wochenschr; 1993; 143(22):571-3. PubMed ID: 7512301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urologic diseases in America project: benign prostatic hyperplasia.
    Wei JT; Calhoun E; Jacobsen SJ
    J Urol; 2005 Apr; 173(4):1256-61. PubMed ID: 15758764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States.
    Taub DA; Wei JT
    Curr Urol Rep; 2006 Jul; 7(4):272-81. PubMed ID: 16930498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Survey of economic burden of hepatitis B-related diseases in 12 areas in China].
    Ma QS; Liang S; Xiao HW; Zhang SX; Zhuang GH; Zou YH; Tan HZ; Liu JC; Zhang YH; Xu AQ; Zhang L; Feng XX; Hu DS; Wang FZ; Cui FQ; Liang XF
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):868-876. PubMed ID: 28738457
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.